

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**October 22, 2009**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Abgenix, Inc.**

**File No. 000-24207 - CF# 24190**

---

Amgen, Inc., (successor to Abgenix, Inc.), submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information Abgenix, Inc. excluded from the Exhibits to a Form 10-Q filed on May 10, 2004.

Based on representations by Amgen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.87                      through October 15, 2014

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kathleen Krebs  
Special Counsel